Last reviewed · How we verify

NCT06302972

Effects of IASTM Along With Comprehensive Corrective Exercise Program in Upper Cross Syndrome.

Recruiting now NA Last updated 19 April 2024
What this trial tests

NA trial testing Traditional treatment in Upper Cross Syndrome in 44 participants. Currently enrolling.

Timeline
30 October 2023
Primary endpoint
30 June 2024
30 June 2024

Quick facts

Lead sponsorRiphah International University
PhaseNA
StatusRecruiting now
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingsingle
Primary purposetreatment
Enrollment44
Start date30 October 2023
Primary completion30 June 2024
Estimated completion30 June 2024
Sites1 location across Pakistan

Drugs / interventions tested

Conditions studied

Sponsor

Riphah International University

Who can join

Adults 18 to 40, any sex, with Upper Cross Syndrome. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study will see the effects of IASTM along with comprehensive corrective exercise program in upper cross syndrome through their effects on pain and cervical ranges as well as postural improvement. Our study targets both male and female population. In the reference study only male population was targeted which did not show effects of both techniques on the female population though females have high stress levels which may alter results.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Traditional treatment

Trials testing the same drug.

Other recruiting trials for Upper Cross Syndrome

Currently open trials in the same condition.

Other Riphah International University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06302972.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing